Trusted Resources: Education
Scientific literature and patient education texts
Free Light Chain Testing for the Diagnosis, Monitoring and Prognostication of AL Amyloidosis
source: Clinical Chemistry and Laboratory Medicine
year: 2016
authors: Mollee P, Merlini G.
summary/abstract:The disease causing agent in systemic AL amyloidosis is a monoclonal immunoglobulin free light chain, or fragments thereof, circulating in the blood. It is not surprising, therefore, that measurement of serum free light chains plays a central role in the management of this disorder. In this paper, we review the utility of the serum free light chain assay in the investigation, prognostication and monitoring of AL amyloidosis. Data on the two currently available commercial assays is compared and some practical applications of the assay’s use are presented. While there are limitations, it is clear that the availability of the free light chain assay in the laboratory is a major advance and plays an essential role in the management of patients with AL amyloidosis.
organization: Princess Alexandra Hospital, Australia; University of Queensland, Australia; University of Pavia, ItalyDOI: 10.1515/cclm-2015-0938
read more
Related Content
-
Prognostic Impact of Immunoparesis at Diagnosis and After Treatment Onset in Patients With Light-Chain AmyloidosisObjectives: Immunoparesis (IP) is a ris...
-
Amyloidosis: What Every Physician Needs to KnowAmyloidosis is a term for diseases cause...
-
Taking Your Next Steps: Life Following hATTR Amyloidosis DiagnosisBeing diagnosed with hATTR amyloidosis...
-
Molecules That Curb Errant Proteins of AL Amyloidosis Point to New Type of TherapyScientists at Scripps Research have iden...
-
Impact of Genetic Testing in Transthyretin (ATTR) Cardiac AmyloidosisPurpose of Review The review's main foc...
-
How to Talk With Your Family About Your hATTR Amyloidosis Diagnosis?Talking to your family members about you...
-
At Least Partial Hematological Response After First Cycle of Treatment Predicts Organ Response and Long-term Surviva...AL amyloidosis is a rare plasma cell dys...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.